ESR1 and breast carcinoma: This kinase activity was due to PI3K, as it was markedly inhibited by its specific antagonist LY294002 and ERα-dependent, because it was present in ERα-positive MCF-7 but not in ERα-negative MDA-MB-231 breast cancer cells (Figure 4B).